Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario

Deborah A. Marshall, Ilia L. Ferrusi, Maureen Trudeau, Natasha B. Leighl, Jeffrey S Hoch, Luiza R. Grazziotin, Hoa Khong, Eleanor Pullenayegum, Craig C. Earle

Research output: Contribution to journalArticle

Abstract

Objectives: We evaluated adherence of human epidermal growth factor receptor-2 testing using immunohistochemistry and fluorescence in situ hybridization, as well as adjuvant trastuzumab treatment according to Canadian guidelines, and predictors of trastuzumab use in early-stage breast cancer in Ontario. Methods: Retrospective cohort of early-stage breast cancer patients identified in the Ontario Cancer Registry. Human epidermal growth factor receptor-2 test type, sequence, result(s), tumor grade, and hormone receptor status were abstracted from Ontario Cancer Registry pathology reports. Trastuzumab treatment was determined from provincial cancer agency records. Other variables were determined from administrative data sources. Logistic regression models were used to estimate adjusted odds ratios for factors associated with guideline adherence. Results: The first human epidermal growth factor receptor-2 test result was the strongest predictor of confirmatory testing (p < 0.05). Human epidermal growth factor receptor-2 testing by immunohistochemistry accounted for the majority of documented first tests (94%; n = 8249). Overall, 27% (n = 2360) of tested patients received a second test by fluorescence in situ hybridization (46%) or immunohistochemistry (49%) assay. Most human epidermal growth factor receptor-2 equivocal patients (89%; n = 784) received a confirmatory test. Among human epidermal growth factor receptor-2-positive patients, only 57% (n = 385) received trastuzumab treatment within the study period. Human epidermal growth factor receptor-2 status was the strongest predictor of trastuzumab use. Younger patients (<70 years at diagnosis) and negative hormone receptor status had higher odds of trastuzumab treatment (p < 0.05) compared to older and positive hormone receptor status patients. Conclusions: Immunohistochemistry use as a first test was largely consistent with Canadian guidelines; however, immunohistochemistry was frequently used as a confirmatory test, which is not guideline-concordant. Monitoring these testing and treating patterns is necessary to optimize health outcomes associated with trastuzumab.

Original languageEnglish (US)
JournalJournal of Oncology Pharmacy Practice
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Ontario
Guidelines
Immunohistochemistry
Hormones
Fluorescence In Situ Hybridization
Therapeutics
Registries
Neoplasms
Logistic Models
Breast Neoplasms
Guideline Adherence
Information Storage and Retrieval
human ERBB2 protein
Trastuzumab
Odds Ratio
Pathology
Health

Keywords

  • Breast cancer
  • human epidermal growth factor receptor-2
  • oncology
  • trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario. / Marshall, Deborah A.; Ferrusi, Ilia L.; Trudeau, Maureen; Leighl, Natasha B.; Hoch, Jeffrey S; Grazziotin, Luiza R.; Khong, Hoa; Pullenayegum, Eleanor; Earle, Craig C.

In: Journal of Oncology Pharmacy Practice, 01.01.2019.

Research output: Contribution to journalArticle

Marshall, Deborah A. ; Ferrusi, Ilia L. ; Trudeau, Maureen ; Leighl, Natasha B. ; Hoch, Jeffrey S ; Grazziotin, Luiza R. ; Khong, Hoa ; Pullenayegum, Eleanor ; Earle, Craig C. / Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario. In: Journal of Oncology Pharmacy Practice. 2019.
@article{f6f7f54f02a046e49fa472d8d55ee95f,
title = "Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario",
abstract = "Objectives: We evaluated adherence of human epidermal growth factor receptor-2 testing using immunohistochemistry and fluorescence in situ hybridization, as well as adjuvant trastuzumab treatment according to Canadian guidelines, and predictors of trastuzumab use in early-stage breast cancer in Ontario. Methods: Retrospective cohort of early-stage breast cancer patients identified in the Ontario Cancer Registry. Human epidermal growth factor receptor-2 test type, sequence, result(s), tumor grade, and hormone receptor status were abstracted from Ontario Cancer Registry pathology reports. Trastuzumab treatment was determined from provincial cancer agency records. Other variables were determined from administrative data sources. Logistic regression models were used to estimate adjusted odds ratios for factors associated with guideline adherence. Results: The first human epidermal growth factor receptor-2 test result was the strongest predictor of confirmatory testing (p < 0.05). Human epidermal growth factor receptor-2 testing by immunohistochemistry accounted for the majority of documented first tests (94{\%}; n = 8249). Overall, 27{\%} (n = 2360) of tested patients received a second test by fluorescence in situ hybridization (46{\%}) or immunohistochemistry (49{\%}) assay. Most human epidermal growth factor receptor-2 equivocal patients (89{\%}; n = 784) received a confirmatory test. Among human epidermal growth factor receptor-2-positive patients, only 57{\%} (n = 385) received trastuzumab treatment within the study period. Human epidermal growth factor receptor-2 status was the strongest predictor of trastuzumab use. Younger patients (<70 years at diagnosis) and negative hormone receptor status had higher odds of trastuzumab treatment (p < 0.05) compared to older and positive hormone receptor status patients. Conclusions: Immunohistochemistry use as a first test was largely consistent with Canadian guidelines; however, immunohistochemistry was frequently used as a confirmatory test, which is not guideline-concordant. Monitoring these testing and treating patterns is necessary to optimize health outcomes associated with trastuzumab.",
keywords = "Breast cancer, human epidermal growth factor receptor-2, oncology, trastuzumab",
author = "Marshall, {Deborah A.} and Ferrusi, {Ilia L.} and Maureen Trudeau and Leighl, {Natasha B.} and Hoch, {Jeffrey S} and Grazziotin, {Luiza R.} and Hoa Khong and Eleanor Pullenayegum and Earle, {Craig C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1078155219850299",
language = "English (US)",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario

AU - Marshall, Deborah A.

AU - Ferrusi, Ilia L.

AU - Trudeau, Maureen

AU - Leighl, Natasha B.

AU - Hoch, Jeffrey S

AU - Grazziotin, Luiza R.

AU - Khong, Hoa

AU - Pullenayegum, Eleanor

AU - Earle, Craig C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: We evaluated adherence of human epidermal growth factor receptor-2 testing using immunohistochemistry and fluorescence in situ hybridization, as well as adjuvant trastuzumab treatment according to Canadian guidelines, and predictors of trastuzumab use in early-stage breast cancer in Ontario. Methods: Retrospective cohort of early-stage breast cancer patients identified in the Ontario Cancer Registry. Human epidermal growth factor receptor-2 test type, sequence, result(s), tumor grade, and hormone receptor status were abstracted from Ontario Cancer Registry pathology reports. Trastuzumab treatment was determined from provincial cancer agency records. Other variables were determined from administrative data sources. Logistic regression models were used to estimate adjusted odds ratios for factors associated with guideline adherence. Results: The first human epidermal growth factor receptor-2 test result was the strongest predictor of confirmatory testing (p < 0.05). Human epidermal growth factor receptor-2 testing by immunohistochemistry accounted for the majority of documented first tests (94%; n = 8249). Overall, 27% (n = 2360) of tested patients received a second test by fluorescence in situ hybridization (46%) or immunohistochemistry (49%) assay. Most human epidermal growth factor receptor-2 equivocal patients (89%; n = 784) received a confirmatory test. Among human epidermal growth factor receptor-2-positive patients, only 57% (n = 385) received trastuzumab treatment within the study period. Human epidermal growth factor receptor-2 status was the strongest predictor of trastuzumab use. Younger patients (<70 years at diagnosis) and negative hormone receptor status had higher odds of trastuzumab treatment (p < 0.05) compared to older and positive hormone receptor status patients. Conclusions: Immunohistochemistry use as a first test was largely consistent with Canadian guidelines; however, immunohistochemistry was frequently used as a confirmatory test, which is not guideline-concordant. Monitoring these testing and treating patterns is necessary to optimize health outcomes associated with trastuzumab.

AB - Objectives: We evaluated adherence of human epidermal growth factor receptor-2 testing using immunohistochemistry and fluorescence in situ hybridization, as well as adjuvant trastuzumab treatment according to Canadian guidelines, and predictors of trastuzumab use in early-stage breast cancer in Ontario. Methods: Retrospective cohort of early-stage breast cancer patients identified in the Ontario Cancer Registry. Human epidermal growth factor receptor-2 test type, sequence, result(s), tumor grade, and hormone receptor status were abstracted from Ontario Cancer Registry pathology reports. Trastuzumab treatment was determined from provincial cancer agency records. Other variables were determined from administrative data sources. Logistic regression models were used to estimate adjusted odds ratios for factors associated with guideline adherence. Results: The first human epidermal growth factor receptor-2 test result was the strongest predictor of confirmatory testing (p < 0.05). Human epidermal growth factor receptor-2 testing by immunohistochemistry accounted for the majority of documented first tests (94%; n = 8249). Overall, 27% (n = 2360) of tested patients received a second test by fluorescence in situ hybridization (46%) or immunohistochemistry (49%) assay. Most human epidermal growth factor receptor-2 equivocal patients (89%; n = 784) received a confirmatory test. Among human epidermal growth factor receptor-2-positive patients, only 57% (n = 385) received trastuzumab treatment within the study period. Human epidermal growth factor receptor-2 status was the strongest predictor of trastuzumab use. Younger patients (<70 years at diagnosis) and negative hormone receptor status had higher odds of trastuzumab treatment (p < 0.05) compared to older and positive hormone receptor status patients. Conclusions: Immunohistochemistry use as a first test was largely consistent with Canadian guidelines; however, immunohistochemistry was frequently used as a confirmatory test, which is not guideline-concordant. Monitoring these testing and treating patterns is necessary to optimize health outcomes associated with trastuzumab.

KW - Breast cancer

KW - human epidermal growth factor receptor-2

KW - oncology

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85067861208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067861208&partnerID=8YFLogxK

U2 - 10.1177/1078155219850299

DO - 10.1177/1078155219850299

M3 - Article

C2 - 31156051

AN - SCOPUS:85067861208

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

ER -